1. Scrip
  2. >>Rare Diseases

Ascendis’ TransCon Positioned To Take On BioMarin’s Voxzogo

 
• By Jessica Merrill

The Danish company released pivotal data for TransCon CNP in children with achondroplasia that appears competitive with BioMarin’s big growth driver.

Ascendis announced positive Phase III data that hit the mark with investors • Source: Shutterstock

Ascendis Pharma A/S is preparing to file a new drug application for TransCon CNP (navepegritide) early next year for treatment of the growth condition achondroplasia after announcing positive results from the Phase III ApproaCH trial on 16 September.

TransCon CNP is intended to rival to BioMarin Pharmaceutical Inc.’s Voxzogo (vosoritide), which was granted accelerated approval by the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.